Information Provided By: 
Fly News Breaks for February 3, 2020
MYOV
Feb 3, 2020 | 06:25 EDT
Citi analyst Mohit Bansal downgraded Myovant Sciences to Neutral from Buy with a price target of $15, down from $25, after resuming coverage of the name. The analyst sees a high likelihood of Relugolix approval and launch in the first half of 2021 for uterine fibroids and prostate cancer. However, However, Bansal thinks the launch could be slow as his doctor checks hint at commercial challenges in both women's health and prostate cancer.
News For MYOV From the Last 2 Days
There are no results for your query MYOV
